Simonetta Buglioni

Dr. Simonetta Buglioni

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in The American Journal of Pathology
Verified
Journal Article
Open access
PDF file
ABAnnamaria Biroccio
Annamaria Biroccio
BBBarbara Benassi
Barbara Benassi
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
CDCarmen D’angelo
Carmen D’angelo
SBSimonetta Buglioni
Simonetta Buglioni
GZGabriella Zupi
Gabriella Zupi
The aim of this study was twofold: to assess the relationship between c-Myb and Bcl-x expression and to evaluate the prognostic significance of their expression in colorectal carcinoma (CRC) patients. Analysis of tumors from 91 CRC patients for expression of c-Myb and Bcl-x revealed a significant relationship between these two proteins. Kaplan-Meier’s analysis showed an increased risk of relapse and death in patients whose tumor specimens displayed high c-Myb levels and Bcl-x positivity. Similar results were also observed excluding Dukes’ D patients. Molecular analysis using three c-Myb-overexpressing LoVo clones indicated that c-Myb overexpression was accompanied by up-regulation of Bcl-xL protein and mRNA. Tumors originating from these clones injected in nude mice were significantly larger than those formed in mice injected with parental or vector-transfected LoVo cells. Moreover, tumors derived from parental and control vector-transfected but not from c-Myb-overexpressing LoVo cells showed high frequency of apoptotic cells. These results provide direct evidence of an association between c-Myb and Bcl-x expression and suggest that expression of both molecules might be a useful prognostic marker in CRC.

13 December 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Daniela TrisciuoglioDaniela Trisciuoglio
Daniela Trisciuoglio
MTMaria Grazia Tupone
Maria Grazia Tupone
MDMarianna Desideri
Marianna Desideri
MMMarta Di Martile
Marta Di Martile
CGChiara Gabellini
Chiara Gabellini
Donatella Del BufaloDonatella Del Bufalo
Donatella Del Bufalo
By using human melanoma and glioblastoma cell lines and their derivative BCL-XL overexpressing clones, we investigated the role of BCL-XL in aggressive features of these two tumor histotypes. We found that in both models, BCL-XL overexpression increased in vitro cell migration and invasion and facilitated tumor cells to form de novo vasculogenic structures. Furthermore, BCL-XL overexpressing cells exhibited higher tumors sphere formation capacity and expressed higher levels of some stem cell markers, supporting the concept that BCL-XL plays essential roles in the maintenance of cancer stem cell phenotype. BCL-XL expression reduction by siRNA, the exposure to a BCL-XL-specific inhibitor and the use of a panel of human melanoma cell lines corroborated the evidence that BCL-XL regulates tumor progression-associated properties. Finally, the vascular markers and the vasculogenic mimicry were up-regulated in the BCL-XL overexpressing xenografts derived from both tumor histotypes. In conclusion, our work brings further support to the understanding of the malignant actions of BCL-XL and, in particular, to the concept that BCL-XL promotes stemness and contributes to the aggressiveness of both melanoma and glioblastoma.

20 March 2000 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMarcella Mottolese
Marcella Mottolese
SBSimonetta Buglioni
Simonetta Buglioni
CBCarla Bracalenti
Carla Bracalenti
MCMarco Andrea Cardarelli
Marco Andrea Cardarelli
LCLuciana Ciabocco
Luciana Ciabocco
FVFranco Maria Venanzi
Franco Maria Venanzi
The Fas ligand (FasL) and its receptor Fas (APO‐1 or CD95) are members, respectively, of the tumor necrosis factor family that, upon interaction with each other, play a key role in the initiation of one apoptotic pathway. Faulty regulation of the Fas system has been described in a variety of human tumors with different histogenetic origin. Here, we describe the expression and distribution of Fas receptor and ligand pair antigens in surgical samples collected from a cohort of 186 patients bearing breast neoplasms (45 benign and 141 malignant lesions). Immunoperoxidase staining of formalin‐fixed tissues showed that 91.1% of benign lesions expressed Fas, which was present in only 56.7% of malignant tumors. On the other hand, FasL was found positive in 22.2% of benign neoplasms and up‐regulated in in situ as well as invasive carcinomas (53.9%). Moreover, in malignant tumors, the expression of receptor and ligand antigens appeared to be inversely related. When these findings were correlated with pathological parameters of prognostic relevance, a significant association was observed between FasL and the presence of metastatic lymph nodes and larger tumor size while Fas expression correlated to node‐negative status and smaller tumor size. Patients with Fas positive tumors exhibited longer disease‐free survival than those with Fas‐negative carcinoma while FasL did not influence patient outcome. These relationships indicate that benign and malignant mammary lesions are characterized by differential cellular expression of Fas and FasL and suggest that a neoplastic Fas negative/FasL positive phenotype may be linked to breast cancer progression. Int. J. Cancer (Pred. Oncol.) 89:127–132, 2000.

4 September 2008 in Breast Cancer Research
Verified
Journal Article
Open access
FNFlavia Novelli
Flavia Novelli
MMMichele Milella
Michele Milella
EMElisa Melucci
Elisa Melucci
ABAnna Di Benedetto
Anna Di Benedetto
ISIsabella Sperduti
Isabella Sperduti
MMMarcella Mottolese
Marcella Mottolese
Introduction: Estrogen receptor-alpha (ER-α) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-β) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-β distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN). Methods: We conducted an observational prospective study using immunohistochemistry to evaluate ER-β expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-β on disease-free survival in the 728 patients with complete follow-up data. Results: ER-β evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-β and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-β positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-α/PgR/Bcl2- tumors. Kaplan-Meier curves and Cox regression analysis identified ER-β as a significant discriminating factor for disease-free survival both in the node-negative LA (P = 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P = 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse. Conclusion: Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-β positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-β isophorms.

31 March 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AFAlessandra Fabi
Alessandra Fabi
ABAnna Di Benedetto
Anna Di Benedetto
GMGiulio Metro
Giulio Metro
LPLetizia Perracchio
Letizia Perracchio
CNCecilia Nisticò
Cecilia Nisticò
MMMarcella Mottolese
Marcella Mottolese
Purpose: To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression.

18 November 1999 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SBSimonetta Buglioni
Simonetta Buglioni
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
MCMaurizio Cosimelli
Maurizio Cosimelli
SVStefania Vasselli
Stefania Vasselli
CDCarmen D'ANgelo
Carmen D'ANgelo
MMMarcella Mottolese
Marcella Mottolese
About 40% of patients with colorectal carcinoma will develop local or distant tumour recurrences. Integrated analyses of bio‐pathological markers, predictive of tumour aggressiveness, may offer a more rational approach to planning adjuvant therapy. To this end, we analysed the correlation between p53 accumulation, Bcl‐2 expression, DNA ploidy, cell proliferation and conventional clinico‐pathological parameters by testing the prognostic significance of these variables in a series of 171 colorectal carcinoma patients with long‐term follow‐up. The relationships among the various bio‐pathological parameters, analysed by multiple correspondence analysis, showed 2 different clinico‐biological profiles. The first, characterised by p53 negativity, Bcl‐2 positivity, diploidy, low percentage of cells in S‐phase (%S‐phase), a low Ki‐67 score, is associated with Dukes' A‐B stage, well differentiated tumours and lack of relapse. The second, defined by p53 positivity, Bcl‐2 negativity, aneuploidy, high %S‐phase and elevated Ki‐67 score, correlates with Dukes' C‐D stage, poorly differentiated tumours and presence of relapse. When these parameters were examined according to Kaplan‐Meier's method, significantly shorter disease‐free (DFS) and overall survival (OS) were also observed in patients bearing p53 positive and Bcl‐2 negative tumours, in Dukes' B stage. In multivariate analysis, p53 accumulation and Bcl‐2 expression emerged as independent predictors of a worse and better clinical outcome, respectively. Our results indicate that, in colorectal adenocarcinomas, a biological profile, based on the combined evaluation of p53 and Bcl‐2, may be useful for identifying high risk patients to be enrolled in an adjuvant setting, mainly in an early stage of the disease. Int. J. Cancer (Pred. Oncol.) 84:545–552, 1999.